Guggenheim analyst Michael Schmidt lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $78 from $80 and keeps a Buy rating on the shares. The firm has “modestly adjusted” its Ogsiveo estimates, reflecting lower assumptions for ovarian granulosa cell tumor contribution and a more gradual sales ramp in 2025 in the EU, the analyst tells investors.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics price target lowered to $55 from $58 at BofA
- SpringWorks Therapeutics initiated with an Outperform at Evercore ISI
- Biotech Alert: Searches spiking for these stocks today
- Immunome price target lowered to $21 from $23 at Piper Sandler
- SpringWorks Therapeutics Q3 2024 Results Overview